MedTrace Logo

Cardiac Dysfunction and Remodeling in Patients With Preeclampsia

NCT04162236 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2020-02-13

No results posted yet for this study

Summary

Preeclampsia (PE) is a pregnancy-related hypertensive disorder drive by an anti-angiogenic environment. Women with PE have 2-4 time higher risk of developing cardiovascular disease (CVD), although the specific mechanism relating these two conditions remains elusive. In non-pregnant patients with coronary disease, angiogenic profile proved to be an independent predictor of poor prognosis and is associated with a higher mortality rate. The investigators hypothesized that in PE, the antiangiogenic environment determines the degree of cardiac dysfunction and remodeling and the posterior cardiovascular risk.

Conditions

  • Preeclampsia
  • Cardiovascular Risk Factor
  • Pregnancy Complications

Interventions

DIAGNOSTIC_TEST

Ecocardiographyc ultrasound

* Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients. * Antropomethric measures * Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity. * Carotid Intima Thickness * Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software * Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays.

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Elisa Llurba · Institut de Recerca Hospital de la Santa Creu i Sant Pau

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-01-01
Completion
2023-01-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162236 on ClinicalTrials.gov